Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.70 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piminodine SCHEMBL1286844 | 0.96 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Piminodine SCHEMBL676858 | 0.95 | KCNA3 (0.64) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11708747 | 0.86 | KCNA3 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL6197539 | 0.84 | KCNA3 (0.77) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.83 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL9064512 | 0.83 | OPRM1 (0.75) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.83 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.82 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9064841 | 0.82 | KCNA3 (0.73) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712071 | 0.82 | OPRM1 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6936 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-12036192-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2024-07-16 | — | — | US | claimed |
| US-11964056-B1 | Tamper resistant dosage forms | PURDUE PHARMA L.P (US) | 2024-04-23 | — | — | US | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| US-5556838-A | BLOCKING N-METHYLASPARTATE RECEPTORS TO PREVENT ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-09-17 | — | — | US | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |